Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA "Drug Watch": Companies Will Have No Input On Content Prior To Posting

This article was originally published in The Pink Sheet Daily

Executive Summary

Sponsors will be notified before products are listed on FDA's drug safety website but will not be given an opportunity to comment on the information ahead of time, Office of New Drugs Director Jenkins says. FDA will be "cautious" regarding the extrapolation of individual product data across a class.

You may also be interested in...



FDA Drug Safety Board May Ask Sponsors To Present At Meetings

“There’s real potential value” to allowing sponsors to present at Drug Safety Oversight Board meetings, board Executive Director Cummins says. Sponsors will not be able to provide input on information to be placed on Drug Watch prior to posting.

FDA Drug Safety Board May Ask Sponsors To Present At Meetings

“There’s real potential value” to allowing sponsors to present at Drug Safety Oversight Board meetings, board Executive Director Cummins says. Sponsors will not be able to provide input on information to be placed on Drug Watch prior to posting.

FDA “Drug Watch” Early Warnings Will Have Lasting Negative Effect, PhRMA Says

A “Drug Watch” listing can do lasting damage to a brand’s reputation based on inadequate data, PhRMA Chief Medical Officer Antony says. The PhRMA exec uses an “extreme” example to highlight his point: imagine “someone reporting that they had early information that you may be a child molester.”

Topics

UsernamePublicRestriction

Register

PS062253

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel